• Nicholas J Shaheen, Bergein F Overholt, Richard E Sampliner, Herbert C Wolfsen, Kenneth K Wang, David E Fleischer, Virender K Sharma, Glenn M Eisen, M Brian Fennerty, John G Hunter, Mary P Bronner, John R Goldblum, Ana E Bennett, Hiroshi Mashimo, Richard I Rothstein, Stuart R Gordon, Steven A Edmundowicz, Ryan D Madanick, Anne F Peery, V Raman Muthusamy, Kenneth J Chang, Michael B Kimmey, Stuart J Spechler, Ali A Siddiqui, Rhonda F Souza, Anthony Infantolino, John A Dumot, Gary W Falk, Joseph A Galanko, Blair A Jobe, Robert H Hawes, Brenda J Hoffman, Prateek Sharma, Amitabh Chak, and Charles J Lightdale.
• Center for Esophageal Diseases and Swallowing, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7080, USA. nshaheen@med.unc.edu
• Gastroenterology. 2011 Aug 1; 141 (2): 460-8.

Background & AimsRadiofrequency ablation (RFA) can eradicate dysplasia and intestinal metaplasia in patients with dysplastic Barrett's esophagus (BE), and reduce rates of esophageal adenocarcinoma. We assessed long-term rates of eradication, durability of neosquamous epithelium, disease progression, and safety of RFA in patients with dysplastic BE.MethodsWe performed a randomized trial of 127 subjects with dysplastic BE; after cross-over subjects were included, 119 received RFA. Subjects were followed for a mean time of 3.05 years; the study was extended to 5 years for patients with eradication of intestinal metaplasia at 2 years. Outcomes included eradication of dysplasia or intestinal metaplasia after 2 and 3 years, durability of response, disease progression, and adverse events.ResultsAfter 2 years, 101 of 106 patients had complete eradication of all dysplasia (95%) and 99 of 106 had eradication of intestinal metaplasia (93%). After 2 years, among subjects with initial low-grade dysplasia, all dysplasia was eradicated in 51 of 52 (98%) and intestinal metaplasia was eradicated in 51 of 52 (98%); among subjects with initial high-grade dysplasia, all dysplasia was eradicated in 50 of 54 (93%) and intestinal metaplasia was eradicated in 48 of 54 (89%). After 3 years, dysplasia was eradicated in 55 of 56 of subjects (98%) and intestinal metaplasia was eradicated in 51 of 56 (91%). Kaplan-Meier analysis showed that dysplasia remained eradicated in >85% of patients and intestinal metaplasia in >75%, without maintenance RFA. Serious adverse events occurred in 4 of 119 subjects (3.4%); the rate of stricture was 7.6%. The rate of esophageal adenocarcinoma was 1 per 181 patient-years (0.55%/patient-years); there was no cancer-related morbidity or mortality. The annual rate of any neoplastic progression was 1 per 73 patient-years (1.37%/patient-years).ConclusionsIn subjects with dysplastic BE, RFA therapy has an acceptable safety profile, is durable, and is associated with a low rate of disease progression, for up to 3 years.Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

29 keywords...

hide…